|Phase of Study:||Phase II|
|Treatment Agents:||CNTO 328|
|Treatment Location:||Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions|
|Estimated Length of Stay in Houston:||Treatment is given in cycles. Each cycle is 21 days. Treatment with study drug |
(either CNTO or placebo) occurs on the 1st day of each cycle.
|Supported By:||Janssen Research & Development, LLC|
|Return Visit:||During cycle 1(Days 1, 8, and 15), participants will visit the doctor 3 times; |
off study/end of treatment (30 days after the last does of study drug).